Home › Cancro alla prostata › Iowa › Cedar Rapids
Studi clinici su Cancro alla prostata a Cedar Rapids, IA
12 studi su Cancro alla prostata cercano partecipanti presso sedi a Cedar Rapids e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
In reclutamentoFase 3
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
In reclutamentoFase 2
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · a 25 mi di distanza
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
In reclutamentoFase 2
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · a 25 mi di distanza
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
In reclutamentoFase 3
- Univ Of Iowa Hospitals And Clinics, Iowa City · a 25 mi di distanza
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
In reclutamentoFase 3
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
In reclutamentoFase 3
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
In reclutamentoFase 1
- University of Iowa Health Care, Iowa City · a 25 mi di distanza
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
In reclutamentoFase 3
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Iowa City · a 25 mi di distanza
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
In reclutamentoFase 3
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · a 25 mi di distanza
Preop Laxatives in Robotic Urologic Surgery
In reclutamentoFase 4Volontari sani benvenuti
- University of Iowa Hospitals & Clinics, Iowa City · a 25 mi di distanza
Studi su Cancro alla prostata in altre città
- New York City, NY103 studi
- Houston, TX76 studi
- Los Angeles, CA61 studi
- Boston, MA59 studi
- St. Louis, MO46 studi
- Chicago, IL45 studi
- San Francisco, CA45 studi
- Philadelphia, PA44 studi
- Baltimore, MD43 studi
- Nashville, TN42 studi
- Seattle, WA42 studi
- Washington, DC38 studi
Altri studi a Cedar Rapids
- Cancro del polmone non a piccole cellule20 studi
- Cancro al seno17 studi
- Leucemia mieloide acuta16 studi
- Cancro (tutti i tipi)15 studi
- Mieloma multiplo15 studi
- Cancro ai polmoni14 studi
- Cancro colorettale13 studi
- Carcinoma a cellule squamose della testa e del collo12 studi
- Melanoma10 studi
- Ictus10 studi
- Cancro metastatico9 studi
- Cancro dell'endometrio9 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.